MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11676-11682

  Yan, Wei ^a,b   Liu, Yanwei ^a,c,d   Yang, Pei ^a,c,d   Wang, Zheng ^a,c,d   You, Yongping ^b   Jiang, Tao ^a,c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; IDH1 mutation; MicroRNA; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; MICRORNA; MICRORNA 1238; MICRORNA 1280; MICRORNA 151 3P; MICRORNA 423 5P; MICRORNA 93; MICRORNA 938; MICRORNA LET 7I; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; EGFR PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHEMOSENSITIVITY; CHINESE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY GLIOBLASTOMA; PRIMARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CHINA; CLINICAL TRIAL; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG RESISTANCE; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHINA; CLUSTER ANALYSIS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MICRORNAS; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84929650188     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3258     Document Type: Article

References (19)

1. Kotliarova S, Fine HA. SnapShot: glioblastoma multiforme. Cancer Cell. 2012;21:710-710e711.
2. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol. 2007;19:598-605.
3. Li C, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009;11:747-757.
4. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69:9065-9072.
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173.
6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
7. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13:e249-258.
8. Yan W, Zhang W, Jiang T. Oncogene addiction in gliomas:implications for molecular targeted therapy. J Exp Clin Cancer Res. 2011;30:58.
9. Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, Bao Z, Zhang W, You Y, Jiang T. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5:12908-12915.
10. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca EA, Lawler S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68:9125-9130.
11. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. 2013;119:814-824.
12. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One. 2012;7:e30339.
13. Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. Clin Cancer Res. 2006;12:7209-7214.
14. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71:2988-2999.
15. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011;71:4055-4060.
16. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011;38:243-253.
17. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res. 2011;71:3387-3399.
18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
19. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crino L, Peschle C, De Maria R. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005;65:11469-11477.